Jonathan Yingling

After several years as a member of the Arcus Scientific Advisory Board, in 2020 Jonathan joined Arcus as Senior Vice President, Research. As a member of the Research Leadership team, Jonathan provides guidance to all aspects of the research, discovery, and translational efforts, creating a key research interface with the Development organization.

Throughout Jonathan’s long tenure in the pharmaceutical/biotech industry, he has held senior leadership positions in the R&D organizations of several pillars of the sector, including BMS (VP, Oncology Discovery & Translational Research), and Lilly (VP Oncology Research and then VP Translational Science & Technology), as well as innovative biotech companies Idera Pharmaceuticals (CSO) and Bind Therapeutics (CSO). He has applied his extensive scientific expertise in oncology and translational research to the discovery and development of multiple cancer drugs. He also established and led global research and translational science partnerships in the U.S., Singapore, China, and Europe. In addition, he championed and led major merger and acquisition transactions. Jonathan has been involved in the discovery and development of more than 15 drug candidates, including galunisertib and merestinib.